Hypercalcemia Malignancy Factor (1-34), human

Hypercalcemia Malignancy Factor (1-34), human (CPC catalog code PTHP-005) is a synthetic bone / cartilage biology peptide in the bone / cartilage category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use Hypercalcemia Malignancy Factor (1-34), human as a reference standard in bone / cartilage workflows — for example, osteoblast / osteoclast differentiation assays and chondrocyte and cartilage-explant remodeling studies. Human clinical evidence is not established.

No. Hypercalcemia Malignancy Factor (1-34), human is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a bone / cartilage workflow, Hypercalcemia Malignancy Factor (1-34), human is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Commonly paired with ALP, TRAP, or Alizarin Red staining in cell-based readouts.

Store lyophilized at −20 °C. Reconstitute in sterile buffer immediately before use. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for PTHP-005. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.